Zealand Pharma — Juni 2024
-
@YPE - Et hurtigt kig: en halveret hover-makering i topnavigationslinksene på Zealands hjemmeside ser bare super dårligt ud!
Læs/se hvordan det evt. kan gøres her:
Nielsen Norman Group: UX Training, Consulting, & Research
A leader in the user experience field, NN/g conducts groundbreaking research, trains and certifies UX practitioners, and provides UX consulting to clients.
Nielsen Norman Group (www.nngroup.com)
-
Zealand Pharma, der torsdag blev højdespringer i C25-indekset, kan igen komme i fokus fredag.
Torsdag steg aktien med 6,6 pct. til 651 kr., efter at data fra et fase 2-studie med lægemiddelkandidaten Survodutid til behandling af fedtlever ved en fejl kortvarigt var lagt ud på en videnskabelig konferences hjemmeside.
De detaljerede resultater fra studiet, der er gennemført af partneren Boehringer Ingelheim, vil efter planen blive offentliggjort på en videnskabelig konference i Milano fredag.
-
mornings:)
-
****ZEALAND: POSITIVT RESULTAT AF FASE 2 FORSØG MED SURVODUTIDE TIL MASH
-
kommer nok løbende nu
-
Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
-
News builds on previously announced primary endpoint, which showed up to 83.0% of adults achieved statistically significant improvement in metabolic dysfunction-associated steatohepatitis (MASH) versus placebo (18.2%).
New data on the secondary endpoint shows up to 52.3% of adults with fibrosis stages F1, F2 and F3 had improvement in fibrosis due to MASH. -
Additional sub-analysis shows up to 64.5% of adults with fibrosis stages F2 and F3 (moderate to advanced scarring) achieved an improvement in fibrosis without worsening of MASH.
Survodutide to advance into Phase 3 MASH study; results reinforce its potential as a best-in-class MASH treatment and, with ongoing trials in obesity, could lead to clinically meaningful benefits across the cardiovascular, renal, and metabolic spectrum. -
We are very excited by the impressive Phase 2 trial results announced today by Boehringer Ingelheim for survodutide in MASH”, said David Kendall, MD, Chief Medical Officer of Zealand Pharma. “These Phase 2 data provide evidence of clear differentiation that positions survodutide as a potential incretin-based treatment for both obesity and MASH. We are delighted that survodutide will advance into Phase 3 for the potential treatment of MASH.”
-
For additional information, please refer to Boehringer Ingelheim’s press release from today available at https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/breakthrough-phase-2-survodutide-data-liver-fibrosis-mash
-
Zealand annoncerer detaljerede resultater fra studie af lægemiddelhåb mod fedtlever https://proinvestor.com/investornyt/1169973/zealand-annoncerer-detaljerede-resultater-fra-studie-af-laegemiddelhab-mod-fedtlever
-
så kører bussen . 673 op 3.3%
-
gætter på at det er efter U investorer er ved at være "på" - ofte mere agressive
-
(USA)
-
tror det ikke var over længere tid - ikke "en" finger
-
Hvordan tror i aktien vil blive påvirket af det nu oplyste fase 2 studie
de næste par uger? Vi fik jo noget af et nøk op sidst, men faldt dog en del efter.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind